Retatrutide and burning skin: what TRIUMPH-1 found

Adults receiving weekly retatrutide injections in TRIUMPH-1 reported dysesthesia more often than adults receiving placebo. The trial recorded a group of altered sensations that included skin burning. It cannot identify the cause of a specific symptom.

Correction, November 14, 2026. The earlier version relied on safety reports and estimates for other drugs to explain burning skin. It also overstated what timing and symptom patterns reveal about the cause. This update uses direct results from TRIUMPH-1 and clarifies their limits.

What the retatrutide trial recorded

TRIUMPH-1 was an 80-week randomized, double-blind phase 3 trial in adults with obesity, or overweight and a weight-related condition, without diabetes. Participants were assigned to weekly subcutaneous retatrutide or placebo. Researchers recorded dysesthesia as an adverse event. The term covered skin burning and related sensations. ^[1]

The trial sponsor’s safety report gives the exact proportions: 0.9% with placebo, 5.1% in the lowest retatrutide group, 12.3% in the middle group and 12.5% in the highest group. The sponsor describes most events as mild to moderate. These percentages cover the broad event category. They cannot tell us how many people experienced burning alone or how long symptoms lasted for a given person.

What the comparison leaves open

More participants reported dysesthesia in the retatrutide groups than in the placebo group. The upper two groups had similar percentages. This trial did not test the biological mechanism of the symptom, determine whether a given person had nerve injury, or compare retatrutide with tirzepatide. A symptom’s timing alone cannot settle those questions.

Do these results apply to a product sold online?

The FDA states that retatrutide is not a component of an approved drug and cannot be used in compounding under U.S. federal law. TRIUMPH-1 used a defined study product. Its results cannot establish what was in a vial sold outside the trial or estimate the risk from that product.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.